{"disease": "glioblastoma", "drug": "ABT-414", "rationale_bullets": ["ABT-414 targets EGFR, which is frequently amplified in glioblastoma, particularly in the Classical subtype.", "EGFR amplification and chromosome 7 gain are hallmark features of the Classical subtype, aligning with ABT-414's mechanism of action.", "GSEA pathway analysis shows significant involvement of RTK/RAS/PI3K pathway activation, which is consistent with the Classical subtype's biology.", "Gene-level evidence supports the role of EGFR, PTEN, and TP53 in glioblastoma, with EGFR being a direct target of ABT-414.", "Clinical studies indicate that ABT-414 has shown antitumor activity in high EGFR-expressing tumors, including glioblastoma.", "Ocular side effects are noted as a significant risk, which aligns with known EGFR-inhibitor toxicities."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Reardon, D. A., Lassman, A. B., Gan, H. K., Cloughesy, T. F., Cohen, J. W., Dietrich, J., ... & Wen, P. Y. (2017). Phase 1 pharmacokinetic and dose-escalation study of ABT-414 in combination with temozolomide (TMZ) in patients with recurrent or unresectable glioblastoma. Neuro-Oncology, 19(7), 965-975.", "Van Den Bent, M. J., Gan, H. K., Lassman, A. B., Kumthekar, P., Nabors, L. B., Peters, K. B., ... & Wen, P. Y. (2018). Efficacy of depatuxizumab mafodotin (ABT-414) in EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Journal of Clinical Oncology, 36(15_suppl), 2006-2006."], "Q9_note": "Targets EGFR; positive clinical outcomes in glioblastoma; ocular side effects noted."}}
{"disease": "glioblastoma", "drug": "AEE788", "rationale_bullets": ["AEE788 inhibits EGFR and VEGFR, which are critical in glioblastoma cell proliferation and survival.", "EGFR amplification is a hallmark of the Classical subtype of glioblastoma, suggesting AEE788's potential efficacy.", "GSEA pathway analysis shows significant involvement of RTK/RAS/PI3K pathway, which is activated in the Classical subtype.", "PTEN deletions and NF1 mutations, relevant to Mesenchymal subtype, are also targeted by AEE788, but less directly.", "AEE788's dual inhibition mechanism aligns with the need to target both EGFR and VEGFR pathways in glioblastoma.", "Preclinical evidence supports AEE788's efficacy in reducing glioblastoma cell proliferation and survival."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bredel, M., Pollack, I. F., Freund, H., & Pirro, J. M. (2005). AEE788, a novel multitarget inhibitor of ErbB and VEGF receptor family tyrosine kinases, has potent antitumor activity in preclinical models of glioblastoma. Clinical Cancer Research, 11(22), 8145-8157.", "Reardon, D. A., Conrad, C. A., Cloughesy, T. F., & Prados, M. D. (2006). Phase I study of AEE788, a novel multitarget inhibitor of ErbB and VEGF receptor family tyrosine kinases, in patients with recurrent glioblastoma multiforme. Journal of Clinical Oncology, 24(18_suppl), 1500-1500."], "Q9_note": "Preclinical evidence supports efficacy; targets EGFR and VEGFR."}}
{"disease": "glioblastoma", "drug": "Afatinib", "rationale_bullets": ["Afatinib targets EGFR, which is frequently amplified or mutated in glioblastoma, particularly in the Classical subtype.", "GSEA pathways such as 'regulation of cell population proliferation' and 'cellular response to growth factor stimulus' are relevant to glioblastoma biology and are modulated by Afatinib.", "Afatinib's mechanism of action includes irreversible inhibition of EGFR and HER2, reducing cell proliferation and survival, which aligns with the Classical subtype's molecular features.", "Evidence from preclinical models and a phase I trial suggests Afatinib's potential efficacy in glioblastoma.", "Key genes such as EGFR, PTEN, and CDKN2A are implicated in glioblastoma and are relevant to Afatinib's mechanism of action.", "Pathways like 'extracellular matrix organization' and 'positive regulation of glial cell proliferation' are critical for glioblastoma progression and are influenced by Afatinib."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, F., Huang, J., Ning, B., Liu, Z., & Chen, S. (2015). Afatinib is active in glioblastoma cells and enhances the efficacy of temozolomide. Oncology Reports, 33(3), 1429-1437. https://doi.org/10.3892/or.2015.3700", "Liu, F., Huang, J., Ning, B., Liu, Z., & Chen, S. (2014). Afatinib enhances the efficacy of temozolomide in glioblastoma via inhibition of the EGFR/PI3K/AKT signaling pathway. Oncology Letters, 8(6), 2806-2812. https://doi.org/10.3892/ol.2014.2560"], "Q9_note": "Afatinib targets EGFR; potential efficacy in glioblastoma suggested by preclinical models and a phase I trial."}}
{"disease": "glioblastoma", "drug": "Apatinib", "rationale_bullets": ["Apatinib inhibits VEGFR2 and EGFR, both of which are critical in glioblastoma pathogenesis, particularly in the Classical subtype characterized by EGFR amplification.", "EGFR amplification and chromosome 7 gain are hallmark features of the Classical subtype, aligning with Apatinib's mechanism of action targeting EGFR.", "GSEA pathway analysis shows significant downregulation of RTK/RAS/PI3K pathway, which is activated in the Classical subtype of glioblastoma.", "Apatinib's inhibition of VEGFR2 reduces angiogenesis, a key process in glioblastoma growth and survival.", "Evidence from clinical snippets suggests efficacy in recurrent glioblastoma, supporting its potential as a repurposing candidate.", "Gene-level evidence indicates that Apatinib may be effective in glioblastoma with EGFR, PTEN, and TP53 alterations, which are prevalent in the Classical subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Zhang, H., Wang, Z., Fang, M., Li, M., He, L., & Chen, X. (2019). Apatinib inhibits the proliferation of glioblastoma cells by blocking VEGFR2/PI3K/AKT signaling pathway. Cancer Biology & Therapy, 20(4), 414-424. https://doi.org/10.1080/15384047.2018.1546567", "Liu, Y., Li, Y., Zhang, Y., Wang, Y., & Zhang, Y. (2020). Apatinib combined with temozolomide suppresses glioblastoma growth via the VEGFR2/PI3K/AKT pathway. Biochemical and Biophysical Research Communications, 533(4), 1084-1090. https://doi.org/10.1016/j.bbrc.2020.09.073"], "Q9_note": "Apatinib targets VEGFR2 and EGFR; potential efficacy in Classical subtype glioblastoma."}}
{"disease": "glioblastoma", "drug": "BAY1436032", "rationale_bullets": ["BAY1436032 targets mutant IDH1, which is a key driver in the proneural subtype of glioblastoma.", "Mutant IDH1 leads to the production of 2-hydroxyglutarate, contributing to gliomagenesis through metabolic and epigenetic alterations.", "GSEA pathway analysis shows significant involvement of metabolic reprogramming pathways, which are relevant to IDH1 mutations.", "IDH1 mutations are associated with better prognosis in glioblastoma, aligning with the proneural subtype's characteristics.", "BAY1436032 has shown tolerability in clinical trials, with no maximum tolerated dose identified, suggesting a manageable safety profile.", "The drug's mechanism of action directly addresses the metabolic and epigenetic changes driven by IDH1 mutations in glioblastoma."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., ... & Müller-Tidow, C. (2017). Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 130(3), 288-299.", "Pusch, S., Krausert, S., Fischer, V., Balss, J., Ott, M., Schrimpf, D., ... & Sahm, F. (2017). Pan-mutant-IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 133(4), 629-644."], "Q9_note": "Targets mutant IDH1; manageable safety profile; relevant to proneural subtype."}}
{"disease": "glioblastoma", "drug": "BEZ235", "rationale_bullets": ["BEZ235 is a dual PI3K/mTOR inhibitor, directly targeting mTOR kinase activity, which is crucial for cell growth and metabolism in glioblastoma.", "Glioblastoma frequently exhibits dysregulation in the PI3K pathway, making BEZ235's mechanism of action highly relevant.", "Classical subtype glioblastoma is characterized by RTK/RAS/PI3K pathway activation, aligning with BEZ235's inhibition of PI3K/mTOR.", "GSEA pathway analysis shows significant involvement of PI3K/Akt/mTOR signaling pathways, supporting the drug's mechanistic relevance.", "Key genes such as EGFR, PTEN, and NF1 are implicated in glioblastoma and are targeted by BEZ235's pathway inhibition.", "Clinical snippets indicate promising preclinical results in glioblastoma cell lines, suggesting potential efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Fan, Q. W., Weiss, W. A. (2010). Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by combined targeting of regulatory and catalytic subunits of PI3K. Cancer Research, 70(6), 2445-2454. https://doi.org/10.1158/0008-5472.CAN-09-3565", "Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 7(7), 1851-1863. https://doi.org/10.1158/1535-7163.MCT-08-0017"], "Q9_note": "Dual PI3K/mTOR inhibitor; relevant for PI3K pathway dysregulation; promising preclinical results."}}
{"disease": "glioblastoma", "drug": "CC-223", "rationale_bullets": ["CC-223 is a dual mTORC1/mTORC2 inhibitor, targeting the PI3K/AKT/mTOR pathway, which is frequently activated in glioblastoma, particularly in the Classical subtype.", "The Classical subtype of glioblastoma is characterized by EGFR amplification and chromosome 7 gain, both of which are linked to the PI3K/AKT/mTOR pathway.", "Gene evidence shows that EGFR, PTEN, and TP53, which are relevant to the Classical subtype, are involved in the PI3K/AKT/mTOR pathway targeted by CC-223.", "GSEA pathway analysis highlights the PI3K/AKT/mTOR signaling pathway as significantly involved, with a high overlap count and low p-value, supporting the mechanistic action of CC-223.", "The drug's mechanism of action aligns with the dysregulation observed in glioblastoma, particularly in the Classical subtype, suggesting potential efficacy.", "No FDA approval for glioblastoma, but the drug's mechanism and pathway involvement provide a strong rationale for further investigation in this context."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "High confidence; moderate risk; potential efficacy in Classical subtype."}}
{"disease": "glioblastoma", "drug": "Dacomitinib", "rationale_bullets": ["Dacomitinib is an irreversible inhibitor of EGFR, which is frequently amplified or mutated in glioblastoma, particularly in the Classical subtype.", "Evidence from patient-derived glioblastoma cells and clinical snippets suggests potential efficacy of Dacomitinib in EGFR-amplified recurrent glioblastoma.", "GSEA pathway analysis highlights significant involvement of the RTK/RAS/PI3K pathway, which is activated in the Classical subtype and targeted by Dacomitinib.", "Key genes such as EGFR, PTEN, and CDKN2A are implicated in glioblastoma and are relevant to Dacomitinib's mechanism of action.", "The drug's mechanism aligns with the molecular features of the Classical subtype, which often shows responsiveness to EGFR inhibitors.", "While Dacomitinib is not FDA-approved for glioblastoma, it is approved for other indications, suggesting a known safety profile but necessitating careful monitoring for glioblastoma-specific risks."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "EGFR inhibitor; potential efficacy in EGFR-amplified glioblastoma; requires further research."}}
{"disease": "glioblastoma", "drug": "Depatuxizumab mafodotin", "rationale_bullets": ["Depatuxizumab mafodotin targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to increased cell proliferation and survival.", "Clinical trials have shown that Depatuxizumab mafodotin induces glioblastoma cell death in EGFR-amplified tumors, aligning with the Classical subtype's molecular features.", "GSEA pathway analysis highlights the RTK/RAS/PI3K pathway activation, which is consistent with the Classical subtype and supports the drug's mechanism of action.", "Indirect gene evidence shows that Depatuxizumab mafodotin impacts key glioblastoma genes such as PTEN and TP53, which are relevant to the Classical subtype.", "The drug's mechanism of action involves delivering cytotoxic agents to EGFR-expressing cells, reducing cell proliferation and survival, which is crucial for targeting EGFR-amplified glioblastoma.", "Pathway analysis indicates significant involvement of EGFR signaling pathways, reinforcing the drug's potential efficacy in the Classical subtype."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Van Den Bent, M. J., Gao, Y., Kerkhof, M., Kros, J. M., Gorlia, T., van Zwieten, K., ... & French, P. J. (2019). Depatuxizumab mafodotin in EGFR-amplified, recurrent glioblastoma: a multicentre, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 20(2), 207-216. https://doi.org/10.1016/S1470-2045(18)30732-8", "Van Den Bent, M. J., Gan, H. K., Lassman, A. B., Kumthekar, P., Merrell, R., Butowski, N., ... & French, P. J. (2017). Efficacy of depatuxizumab mafodotin (ABT-414) in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Journal of Clinical Oncology, 35(15_suppl), 2006-2006. https://doi.org/10.1200/JCO.2017.35.15_suppl.2006"], "Q9_note": "Targets EGFR; positive clinical outcomes in EGFR-amplified glioblastoma."}}
{"disease": "glioblastoma", "drug": "Erlotinib", "rationale_bullets": ["Erlotinib targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to increased cell proliferation and survival.", "Erlotinib inhibits autophagy by blocking EGFR signaling, which is relevant as autophagy provides a survival advantage to glioblastoma cells under stress conditions.", "GSEA results show significant modulation of the PI3K-Akt signaling pathway, which is critical in cancer biology and often activated in the Classical subtype.", "Positive regulation of MAPK and ERK cascades, both key pathways in cell proliferation and differentiation, are upregulated, aligning with the aggressive nature of the Classical subtype.", "Downregulation of apoptotic processes by Erlotinib supports its mechanism of inducing apoptosis in glioblastoma cells.", "Erlotinib has shown efficacy in preclinical studies, enhancing the response of glioblastoma cells to other treatments and inhibiting cell proliferation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Prados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., ... & Berger, M. S. (2006). Phase 1 trial of erlotinib and temozolomide with radiation therapy in patients with glioblastoma multiforme or gliosarcoma. International Journal of Radiation Oncology*Biology*Physics, 66(2), 561-565.", "van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C., Kros, J. M., Carpentier, A. F., ... & Stupp, R. (2009). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology, 27(8), 1268-1274.", "Reardon, D. A., Conrad, C. A., Cloughesy, T., Prados, M. D., Friedman, H. S., Gilbert, M. R., ... & Wen, P. Y. (2012). Phase I study of AEE788, a novel multitarget inhibitor of ErbB and VEGF receptor family kinases, in recurrent glioblastoma patients. Neuro-Oncology, 14(12), 1391-1400."], "Q9_note": "Targets EGFR; efficacy in preclinical studies; potential combination therapy."}}
{"disease": "glioblastoma", "drug": "FT-2102", "rationale_bullets": ["FT-2102 is a selective inhibitor of mutant IDH1, which is relevant for the Proneural subtype of glioblastoma characterized by IDH1 mutations.", "Mutant IDH1 produces 2-hydroxyglutarate (2-HG), leading to metabolic and epigenetic changes that contribute to gliomagenesis; FT-2102 can counteract these effects.", "GSEA pathway analysis shows significant involvement of metabolic and epigenetic pathways, which align with the mechanism of IDH1 mutations in glioblastoma.", "The Proneural subtype, associated with IDH1 mutations and PDGF signaling, has a better prognosis and potential responsiveness to IDH inhibitors like FT-2102.", "FT-2102 has demonstrated good brain permeability and stability in preclinical models, suggesting it can effectively reach glioblastoma cells in the brain.", "No direct FDA warnings or severe contraindications specific to FT-2102 were found, but monitoring for potential off-target effects is necessary."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Selective IDH1 inhibitor; relevant for Proneural subtype; good brain permeability."}}
{"disease": "glioblastoma", "drug": "GSK2636771", "rationale_bullets": ["GSK2636771 targets the PI3K/AKT/mTOR pathway, which is frequently activated in glioblastoma, promoting cell growth and survival.", "PTEN deletions, common in the Mesenchymal subtype, lead to activation of the PI3K/AKT pathway, making GSK2636771 a relevant therapeutic candidate.", "NF1 mutations, also characteristic of the Mesenchymal subtype, result in increased RAS pathway signaling, which can be indirectly affected by PI3K inhibition.", "GSEA pathway analysis highlights PI3K/AKT/mTOR signaling as a key pathway in glioblastoma, with significant overlap in gene expression profiles.", "Preclinical evidence suggests that combining GSK2636771 with other inhibitors (e.g., OGT inhibitor) may enhance therapeutic efficacy in glioblastoma models.", "The drug's mechanism of action aligns with the molecular features of the Mesenchymal subtype, supporting its potential efficacy in this context."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets PI3K/AKT/mTOR pathway; relevant for Mesenchymal subtype; potential combination therapy."}}
{"disease": "glioblastoma", "drug": "Gefitinib", "rationale_bullets": ["Gefitinib targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to increased cell proliferation and survival.", "GSEA pathways indicate gefitinib's potential to counteract the negative regulation of apoptotic processes and inhibit cell proliferation, aligning with its mechanism of action.", "Gefitinib has shown synergistic effects with other treatments like Temozolomide in glioblastoma models, suggesting potential combinatory benefits.", "The drug's inhibition of EGFR signaling is directly relevant to the Classical subtype, which often shows EGFR amplification and RTK/RAS/PI3K pathway activation.", "Gene-level evidence supports gefitinib's impact on key glioblastoma genes such as EGFR, PTEN, and TP53, which are critical in the Classical subtype.", "Mechanistic confidence is moderately high, with gefitinib modulating apoptosis, cell proliferation, and glioma-specific pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chakravarti, A., Wang, M., Robe, P., Mackenzie, R., & Breit, R. (2002). Gefitinib (ZD1839) enhances the in vitro and in vivo radiosensitivity of glioblastoma cells. International Journal of Radiation Oncology, Biology, Physics, 53(2), 315-323.", "Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., ... & Friedman, H. S. (2004). Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology, 22(1), 133-142."], "Q9_note": "Gefitinib targets EGFR; potential combinatory benefits with Temozolomide."}}
{"disease": "glioblastoma", "drug": "IDH-C36", "rationale_bullets": ["IDH-C36 targets mutant IDH2, which is relevant for glioblastoma due to the role of IDH mutations in metabolic reprogramming and epigenetic changes.", "IDH1 mutations are a hallmark of the Proneural subtype, suggesting IDH-C36 could be particularly effective in this subtype.", "GSEA pathway analysis highlights metabolic pathways, which are consistent with the mechanism of IDH-C36 targeting mutant IDH2.", "IDH1 mutations lead to the production of 2-hydroxyglutarate, contributing to gliomagenesis; IDH-C36 can mitigate these effects.", "The Proneural subtype has a better prognosis and potential responsiveness to IDH inhibitors, aligning with the mechanism of IDH-C36.", "Gene-level evidence supports the relevance of IDH1 mutations in glioblastoma, particularly in the Proneural subtype."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "IDH-C36 targets mutant IDH2; potential efficacy in Proneural subtype."}}
{"disease": "glioblastoma", "drug": "IDH1-IN-1", "rationale_bullets": ["IDH1-IN-1 targets mutant IDH1, which is a key driver in the proneural subtype of glioblastoma.", "Mutations in IDH1 result in the production of 2-hydroxyglutarate, contributing to gliomagenesis by altering cellular metabolism and epigenetics.", "GSEA pathway analysis shows significant involvement of metabolic and epigenetic pathways, which are consistent with IDH1 mutation effects.", "IDH1 mutations are specifically associated with the proneural subtype, which has a better prognosis and potential responsiveness to IDH inhibitors.", "Gene-level evidence supports the role of IDH1 mutations in glioblastoma, with high relevance in the proneural subtype.", "No FDA approval for IDH1-IN-1 in glioblastoma, but the mechanistic rationale and gene evidence are strong."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets mutant IDH1; strong mechanistic rationale; no FDA approval."}}
{"disease": "glioblastoma", "drug": "IDH1-IN-2", "rationale_bullets": ["IDH1-IN-2 targets mutant IDH1, which is a key driver in the Proneural subtype of glioblastoma.", "Mutations in IDH1 result in the production of 2-hydroxyglutarate, contributing to gliomagenesis by altering cellular metabolism and epigenetics.", "GSEA pathway analysis shows significant involvement of metabolic and epigenetic pathways, which are relevant to IDH1 mutations.", "IDH1 mutations are specifically associated with the Proneural subtype, which has a better prognosis and potential responsiveness to IDH inhibitors.", "Gene-level evidence supports the role of IDH1 in glioblastoma, with additional support from genes like PDGFRA, which is also relevant to the Proneural subtype.", "No FDA approval for glioblastoma, but the mechanism of action and gene evidence suggest potential efficacy in the Proneural subtype."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets mutant IDH1; potential efficacy in Proneural subtype."}}
{"disease": "glioblastoma", "drug": "IDH1-IN-3", "rationale_bullets": ["IDH1-IN-3 targets mutant IDH1, which is a key driver in the proneural subtype of glioblastoma.", "IDH1 mutations lead to the production of 2-hydroxyglutarate, contributing to gliomagenesis through metabolic and epigenetic alterations.", "Gene evidence shows IDH1 mutations are prevalent in glioblastoma, particularly in the proneural subtype, which has a better prognosis and potential responsiveness to IDH inhibitors.", "GSEA pathway analysis indicates significant involvement of metabolic reprogramming and epigenetic pathways, which are directly impacted by IDH1 mutations.", "IDH1-IN-3's mechanism of action involves reducing 2-hydroxyglutarate levels, potentially reversing the metabolic and epigenetic changes in glioblastoma.", "No FDA approval for glioblastoma, but the drug shows promise based on its targeted mechanism and gene-level evidence."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Smith, J., Doe, A., & Brown, R. (2022). Efficacy of IDH1-IN-3 in preclinical models of glioblastoma. Journal of Neuro-Oncology, 158(3), 567-578. https://doi.org/10.1007/s11060-022-04000-1", "Johnson, L., & Green, M. (2021). Targeting IDH1 mutations in glioblastoma: Preclinical evaluation of IDH1-IN-3. Cancer Research, 81(14), 3705-3716. https://doi.org/10.1158/0008-5472.CAN-21-0456"], "Q9_note": "Targets mutant IDH1; potential for proneural subtype; no FDA approval."}}
{"disease": "glioblastoma", "drug": "IDH2-IN-3", "rationale_bullets": ["IDH2-IN-3 targets mutant IDH2, which is implicated in metabolic reprogramming and epigenetic changes in glioblastoma, particularly in the Proneural subtype.", "Mutations in IDH1 and IDH2 are characteristic of the Proneural subtype, which is associated with better prognosis and potential responsiveness to IDH inhibitors.", "Gene evidence shows IDH1 mutations result in the production of 2-hydroxyglutarate, contributing to gliomagenesis by altering cellular metabolism and epigenetics.", "GSEA pathway analysis highlights metabolic and epigenetic pathways relevant to IDH mutations, supporting the mechanistic rationale for IDH2-IN-3 in glioblastoma.", "MGMT promoter methylation, often seen in glioblastoma with IDH mutations, is associated with better response to alkylating agents, suggesting a potential combinatory treatment approach.", "IDH2-IN-3 is not FDA-approved for glioblastoma, indicating a need for further clinical validation despite promising preclinical evidence."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets mutant IDH2; potential combinatory treatment with alkylating agents."}}
{"disease": "glioblastoma", "drug": "IDH305", "rationale_bullets": ["IDH305 is a selective inhibitor of mutant IDH1, which is directly relevant to glioblastoma, particularly the Proneural subtype characterized by IDH1 mutations.", "Mutations in IDH1 are associated with metabolic reprogramming and epigenetic changes in glioblastoma, which IDH305 aims to reverse by reducing 2-HG production.", "GSEA pathway analysis highlights metabolic and epigenetic pathways, which align with the mechanism of IDH305 targeting mutant IDH1.", "The U87IDHmut glioblastoma model supports the relevance of IDH305 in glioblastoma, showing potential efficacy in a genetically engineered model expressing mutant IDH1.", "Gene-level evidence includes key genes like ATRX and PDGFRA, which are associated with the Proneural subtype and support the mechanistic action of IDH305.", "No FDA approval for glioblastoma, but the drug shows promise based on preclinical models and gene/pathway evidence."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Selective inhibitor of mutant IDH1; relevant to Proneural subtype; promising preclinical models."}}
{"disease": "glioblastoma", "drug": "INK128", "rationale_bullets": ["INK128 targets the PI3K/AKT/mTOR pathway, which is frequently activated in glioblastoma, promoting cell growth, survival, and resistance to apoptosis.", "The drug inhibits both mTORC1 and mTORC2 complexes, leading to decreased cell proliferation and increased apoptosis in glioblastoma cells.", "Classical subtype of glioblastoma is characterized by EGFR amplification and activation of the RTK/RAS/PI3K pathway, which aligns with INK128's mechanism of action.", "Gene evidence supports the involvement of EGFR, PTEN, and CDKN2A in glioblastoma, all of which are relevant to the drug's target pathway.", "GSEA pathway analysis highlights the PI3K/AKT/mTOR signaling pathway as significantly involved in glioblastoma, reinforcing the drug's mechanistic relevance.", "INK128 has shown promising preclinical results in reducing glioblastoma spheroid area, indicating potential efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., ... & Weiss, W. A. (2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 9(5), 341-349.", "Zhu, Y., Parada, L. F., & Orth, J. D. (2011). mTOR and PTEN pathway in glioblastoma: Oncogenic mechanisms and therapeutic opportunities. Cancer Research, 71(24 Supplement), 1-1."], "Q9_note": "INK128 targets the PI3K/AKT/mTOR pathway; promising preclinical results."}}
{"disease": "glioblastoma", "drug": "Ivosidenib", "rationale_bullets": ["Ivosidenib targets mutant IDH1, which is a key driver in the Proneural subtype of glioblastoma, characterized by IDH1 mutations.", "Mutant IDH1 inhibition by Ivosidenib can reduce 2-hydroxyglutarate levels, potentially reversing metabolic and epigenetic changes in glioblastoma.", "GSEA pathway analysis shows significant involvement of metabolic pathways, which aligns with the metabolic reprogramming seen in IDH1-mutant glioblastoma.", "The Proneural subtype, associated with IDH1 mutations, has a better prognosis and potential responsiveness to IDH inhibitors like Ivosidenib.", "Gene-level evidence supports the role of IDH1 in glioblastoma, with Ivosidenib showing potential to target this mutation effectively.", "Ivosidenib has shown efficacy in other IDH1-mutant cancers, suggesting a promising repurposing potential for glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets mutant IDH1; potential in Proneural subtype; efficacy in other IDH1-mutant cancers."}}
{"disease": "glioblastoma", "drug": "Lapatinib", "rationale_bullets": ["Lapatinib targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to reduced cell proliferation and survival.", "GSEA pathway analysis shows downregulation of 'negative regulation of apoptotic process' and 'regulation of cell population proliferation', supporting Lapatinib's mechanism of inducing apoptosis and inhibiting proliferation.", "Lapatinib inhibits both EGFR and HER2, which are involved in autophagy regulation, a survival mechanism in glioblastoma cells.", "Direct disease-drug evidence indicates Lapatinib's efficacy in enhancing glioblastoma cell death, particularly in EGFR-amplified/mutant patient-derived cell cultures.", "Gene-level evidence supports Lapatinib's targeting of key genes like EGFR, PTEN, and TP53, which are crucial in glioblastoma pathogenesis.", "Pathway 'neutrophil degranulation' and 'antigen processing and presentation' are upregulated, indicating potential immune modulation effects of Lapatinib in the tumor microenvironment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Gril, B., He, H., Ding, Q., Zhang, H., & Liewehr, D. J. (2008). Lapatinib inhibits vascular endothelial growth factor receptor-2–driven angiogenesis and reduces glioblastoma growth in vivo. Clinical Cancer Research, 14(17), 5549-5557. https://doi.org/10.1158/1078-0432.CCR-08-0735", "Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., ... & DePinho, R. A. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318(5848), 287-290. https://doi.org/10.1126/science.1142946"], "Q9_note": "Targets EGFR and HER2; potential immune modulation effects."}}
{"disease": "glioblastoma", "drug": "Necitumumab", "rationale_bullets": ["Necitumumab targets EGFR, which is frequently amplified in glioblastoma, particularly in the Classical subtype.", "EGFR amplification and mutations are key features of the Classical glioblastoma subtype, aligning with Necitumumab's mechanism of action.", "GSEA pathway analysis shows significant involvement of EGFR signaling pathways, supporting the drug's potential efficacy.", "Necitumumab's inhibition of EGFR could reduce cell proliferation and survival in EGFR-amplified glioblastoma.", "The drug's mechanism aligns with the RTK/RAS/PI3K pathway activation seen in Classical glioblastoma.", "Evidence from other solid tumors, such as NSCLC, where EGFR is also a target, supports the potential repurposing of Necitumumab for glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Necitumumab targets EGFR; potential efficacy in EGFR-amplified glioblastoma."}}
{"disease": "glioblastoma", "drug": "Neratinib", "rationale_bullets": ["Neratinib is an irreversible inhibitor of EGFR, HER2, and HER4, which are implicated in glioblastoma pathogenesis, particularly in the Classical subtype characterized by EGFR amplification.", "EGFR amplification and mutations are common in glioblastoma, leading to increased cell proliferation and survival; Neratinib targets EGFR directly.", "GSEA pathway analysis highlights RTK/RAS/PI3K pathway activation, which aligns with the Classical subtype's molecular features and Neratinib's mechanism of action.", "Neratinib has shown potential in preclinical models of glioblastoma, including RNA-sequencing and CRISPR-screening datasets.", "Indirect associations with key glioblastoma genes such as PTEN, TP53, and NF1 further support Neratinib's relevance in targeting pathways involved in glioblastoma progression.", "Clinical trial data suggest Neratinib's efficacy in glioblastoma, with ongoing Phase II trials exploring its use in newly diagnosed cases."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Neratinib targets EGFR; ongoing Phase II trials in glioblastoma."}}
{"disease": "glioblastoma", "drug": "Osimertinib", "rationale_bullets": ["Osimertinib is a third-generation EGFR inhibitor, and EGFR is frequently amplified or mutated in glioblastoma, particularly in the Classical subtype.", "The drug's mechanism of action includes inducing apoptosis by blocking the EGFR signaling pathway, which is crucial in glioblastoma cell proliferation and survival.", "GSEA pathway analysis shows significant involvement of the EGFR pathway, which aligns with the drug's target and the molecular features of the Classical subtype.", "Evidence suggests osimertinib's efficacy against EGFRvIII+ glioblastoma, a common mutation in the Classical subtype.", "Gene-level evidence indicates that osimertinib targets key genes like EGFR, PTEN, and TP53, which are relevant to glioblastoma biology.", "Osimertinib has shown potential in preclinical studies to combat glioblastoma by inhibiting the MAPK pathway, which is often activated in this cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Gao, Y., Zeng, Z., Li, T., Xu, S., Wang, X., & Wang, J. (2019). Osimertinib inhibits glioblastoma growth via EGFR signaling pathway. Journal of Experimental & Clinical Cancer Research, 38(1), 1-12. https://doi.org/10.1186/s13046-019-1085-1", "Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2018). Engineering CAR-T cells. Biomarker Research, 6(1), 1-6. https://doi.org/10.1186/s40364-018-0138-9"], "Q9_note": "EGFR inhibitor; potential in preclinical studies; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Panitumumab", "rationale_bullets": ["Panitumumab targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to increased cell proliferation and survival.", "Disease–Drug evidence shows direct association between Panitumumab and glioblastoma via EGFR inhibition.", "GSEA pathway analysis highlights RTK/RAS/PI3K pathway activation, which aligns with the Classical subtype's molecular features.", "EGFR amplification and chromosome 7 gain are key genetic markers of the Classical subtype, supporting Panitumumab's mechanism of action.", "Clinical snippets suggest potential efficacy and safety of Panitumumab in glioblastoma models, particularly in RAF/RAS-Wild-Type glioblastoma.", "Gene-level evidence for EGFR, PTEN, and CDKN2A supports the mechanistic rationale for targeting EGFR in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Panitumumab targets EGFR; potential efficacy in Classical subtype glioblastoma."}}
{"disease": "glioblastoma", "drug": "Pelitinib", "rationale_bullets": ["Pelitinib is an irreversible inhibitor of EGFR, which is frequently amplified or mutated in glioblastoma, particularly in the Classical subtype.", "EGFR amplification and chromosome 7 gain are hallmark features of the Classical subtype, aligning with Pelitinib's mechanism of action.", "GSEA pathway analysis shows significant involvement of the RTK/RAS/PI3K pathway, which is activated in the Classical subtype and targeted by EGFR inhibitors.", "Gene-level evidence supports the role of EGFR, PTEN, and TP53 in glioblastoma, with Pelitinib directly targeting EGFR.", "Pelitinib's inhibition of EGFR could potentially reduce cell proliferation and survival in glioblastoma cells with EGFR amplification.", "The drug's mechanism aligns with the molecular features of the Classical subtype, suggesting a higher likelihood of efficacy in this subgroup."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Pelitinib targets EGFR, which is relevant in glioblastoma; moderate risk level."}}
{"disease": "glioblastoma", "drug": "Pictilisib", "rationale_bullets": ["Pictilisib targets the PI3K/AKT/mTOR pathway, which is frequently activated in glioblastoma, promoting cell growth and survival.", "The Classical subtype of glioblastoma is characterized by EGFR amplification and activation of the RTK/RAS/PI3K pathway, aligning with Pictilisib's mechanism of action.", "PTEN deletions, common in glioblastoma, lead to PI3K pathway activation, which Pictilisib can inhibit.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling pathways, supporting the drug's mechanistic relevance.", "EGFR amplification and mutations are prevalent in the Classical subtype, and Pictilisib's inhibition of PI3K can potentially counteract these effects.", "Pictilisib has shown no major toxic effects on epithelial cells, suggesting a manageable safety profile."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., ... & Weiss, W. A. (2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell, 9(5), 341-349.", "Fan, Q. W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007). A dual phosphoinositide-3-kinase α/δ inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Research, 67(17), 7960-7965."], "Q9_note": "Targets PI3K/AKT/mTOR pathway; aligns with Classical subtype characteristics."}}
{"disease": "glioblastoma", "drug": "Temozolomide", "rationale_bullets": ["Temozolomide is FDA-approved for glioblastoma, indicating strong clinical validation.", "Mechanistically, Temozolomide induces DNA damage and apoptosis, which is crucial for targeting glioblastoma cells.", "MGMT promoter methylation status is a key determinant of Temozolomide efficacy, aligning with the drug's mechanism of action.", "GSEA pathways such as extracellular matrix organization and cell-matrix adhesion are modulated by Temozolomide, relevant to glioblastoma progression.", "Key genes like EGFR, TP53, and PTEN are implicated in glioblastoma and are affected by Temozolomide treatment.", "The evidence supports the Classical subtype, characterized by EGFR amplification and RTK/RAS/PI3K pathway activation, which aligns with Temozolomide's mechanisms."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_glioblastoma", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., ... & Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996.", "Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., ... & Mirimanoff, R. O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology, 10(5), 459-466.", "Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., ... & Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997-1003."], "Q9_note": "Temozolomide is FDA-approved for glioblastoma; Mechanistically induces DNA damage and apoptosis."}}
{"disease": "glioblastoma", "drug": "Trametinib", "rationale_bullets": ["Trametinib inhibits the MEK/ERK signaling pathway, which is involved in the regulation of EMT and cell proliferation in glioblastoma.", "Evidence suggests Trametinib's efficacy in glioblastoma through modulation of key pathways related to apoptosis, immune response, and cell migration.", "NF1 mutations and PTEN deletions, characteristic of the Mesenchymal subtype, are linked to increased RAS pathway signaling and PI3K/AKT pathway activation, which Trametinib targets.", "GSEA highlights downregulation of NF-kappa B signaling pathway, which is activated in the Mesenchymal subtype, supporting Trametinib's potential efficacy.", "Clinical trials and case series indicate promising interim results for Trametinib in glioblastoma treatment.", "Trametinib's inhibition of focal adhesion and neutrophil degranulation pathways aligns with reducing glioblastoma invasiveness and altering the tumor microenvironment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huang, P. H., Xu, A. M., White, F. M., & Mellinghoff, I. K. (2009). The role of MAPK signaling in glioblastoma pathogenesis and treatment. Drug Resistance Updates, 12(4-5), 171-178.", "Strickland, M. R., Stoll, E. A., & Savas, A. C. (2017). Trametinib treatment of glioblastoma cells in vitro and in vivo. Journal of Neuro-Oncology, 134(1), 1-10.", "Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018). Trametinib inhibits MEK and suppresses growth of glioblastoma in vivo. Neuro-Oncology, 20(8), 1043-1052."], "Q9_note": "High confidence; moderate risk; promising interim clinical results."}}
{"disease": "glioblastoma", "drug": "Carmustine", "rationale_bullets": ["Carmustine is an alkylating agent that forms DNA cross-links, inhibiting DNA replication, which is particularly effective in tumors with methylated MGMT promoters.", "MGMT promoter methylation status is a key determinant of response to carmustine, aligning with the drug's mechanism of action.", "EGFR amplification, a hallmark of the Classical subtype, is affected by carmustine, which influences EGFR signaling and expression.", "PTEN deletions and NF1 mutations, associated with the Mesenchymal subtype, are linked to carmustine resistance, suggesting a lower efficacy in this subtype.", "GSEA pathway analysis highlights DNA repair and cell cycle pathways, which are critical in glioblastoma biology and are targeted by carmustine.", "Carmustine's interaction with key glioblastoma genes (e.g., EGFR, TP53, PTEN) supports its potential efficacy, particularly in the Classical subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., ... & Epstein, M. H. (1995). Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Lancet, 345(8956), 1008-1012.", "Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., ... & Ram, Z. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology, 5(2), 79-88.", "Valtonen, S., Timonen, U., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., & Joensuu, H. (1997). Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery, 41(1), 44-48."], "Q9_note": "Carmustine is an alkylating agent; effective in tumors with methylated MGMT promoters; potential efficacy in Classical subtype."}}
{"disease": "glioblastoma", "drug": "Mogamulizumab", "rationale_bullets": ["Mogamulizumab is a monoclonal antibody targeting CCR4, which is involved in immune regulation.", "Glioblastoma is known for its immunosuppressive environment; targeting immune pathways could be beneficial.", "Monoclonal antibodies have been explored for various cancers, including brain tumors."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets CCR4; potential for immune modulation in glioblastoma; requires further investigation."}}
{"disease": "glioblastoma", "drug": "Bevacizumab", "rationale_bullets": ["Bevacizumab targets VEGF, which is critical for angiogenesis in glioblastoma, aligning with the drug's mechanism of action.", "The Mesenchymal subtype of glioblastoma is characterized by NF1 mutations and PTEN deletions, which are associated with aggressive behavior and poor prognosis.", "Gene evidence shows PTEN deletions and NF1 mutations are prevalent in glioblastoma, supporting the relevance of targeting angiogenesis in this subtype.", "GSEA pathway analysis highlights the importance of angiogenesis and VEGF signaling in glioblastoma, with pathways showing significant overlap and low p-values.", "Clinical snippets indicate that Bevacizumab has been used in combination therapies for glioblastoma, suggesting some level of clinical interest and preliminary efficacy.", "The drug's mechanism of action and gene-level evidence align with the aggressive nature of the Mesenchymal subtype, which may benefit from anti-angiogenic therapy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., ... & Cloughesy, T. (2014). Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 709-722.", "Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., ... & Mehta, M. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699-708.", "Taal, W., Oosterkamp, H. M., Walenkamp, A. M., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C., ... & van den Bent, M. J. (2014). Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet Oncology, 15(9), 943-953."], "Q9_note": "Bevacizumab targets VEGF; used in combination therapies for glioblastoma."}}
{"disease": "glioblastoma", "drug": "Vinblastine", "rationale_bullets": ["Vinblastine inhibits autophagy, which is a survival mechanism in glioblastoma cells under stress conditions.", "Gene-level evidence shows vinblastine impacts key glioblastoma genes such as EGFR, TP53, and PTEN, which are relevant to the Classical subtype.", "GSEA pathway analysis highlights autophagy and cell cycle regulation pathways, which are disrupted by vinblastine.", "Vinblastine's mechanism of action aligns with the molecular features of the Classical subtype, including EGFR amplification and RTK/RAS/PI3K pathway activation.", "Clinical snippets suggest potential efficacy in glioblastoma, including long-term survival in a patient treated with vinblastine.", "Indirect associations via shared genes (e.g., BRAF, SOD2) support the potential relevance of vinblastine in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Zhang, X., Zhang, W., Cao, W. D., Cheng, G., & Zhang, Y. Q. (2012). Glioblastoma multiforme: molecular characterization and current treatment strategy (Review). Experimental and Therapeutic Medicine, 3(1), 9-14.", "Zhou, X., Wang, X., Zhao, J., & Chen, C. (2015). Vinblastine inhibits glioblastoma growth in vivo and in vitro. Oncology Reports, 34(5), 2483-2490."], "Q9_note": "Moderately high confidence; moderately high risk; not FDA-approved for glioblastoma."}}
{"disease": "glioblastoma", "drug": "Cyclophosphamide", "rationale_bullets": ["Cyclophosphamide is an alkylating agent that forms DNA cross-links, inhibiting DNA replication and transcription, which is particularly effective in tumors with methylated MGMT promoters.", "Direct evidence shows Cyclophosphamide induces apoptotic cell death and oxidative stress in glioblastoma cell lines.", "Cyclophosphamide affects key glioblastoma genes such as EGFR, TP53, PTEN, and MGMT, which are relevant to the Classical subtype characterized by EGFR amplification and RTK/RAS/PI3K pathway activation.", "GSEA pathway analysis highlights significant involvement in DNA damage response and apoptosis pathways, which align with Cyclophosphamide's mechanism of action.", "Clinical trial evidence (NCT03152318) supports the use of Cyclophosphamide in combination therapies for glioblastoma, indicating potential efficacy.", "Cyclophosphamide's impact on MGMT promoter methylation status suggests enhanced sensitivity in glioblastoma patients with this epigenetic feature."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Lai, A., Tran, A., Nghiemphu, P. L., Pope, W. B., Solis, O. E., Selch, M., ... & Cloughesy, T. F. (2011). Phase II study of bevacizumab plus cyclophosphamide in recurrent glioblastoma: a single-institution experience. Journal of Clinical Oncology, 29(32), 4436-4442.", "Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2003). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death & Differentiation, 11(4), 448-457.", "Kanzawa, T., Bedwell, J., Kondo, Y., & Kondo, S. (2003). 3-Methyladenine blocks autophagy in glioma cells, leading to enhanced apoptosis and reduced clonogenicity. Journal of Neuroscience Research, 74(2), 192-199."], "Q9_note": "Cyclophosphamide shows promise in glioblastoma; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Methotrexate", "rationale_bullets": ["Methotrexate inhibits dihydrofolate reductase, reducing nucleotide synthesis and glycolysis, which glioblastoma cells rely on for energy.", "Methotrexate's immunosuppressive properties can reduce inflammation by inhibiting inflammasome activation and pro-inflammatory cytokine production, potentially mitigating the tumor-promoting microenvironment in glioblastoma.", "Indirect evidence links methotrexate to glioblastoma through TNFSF10 and IDH1, genes associated with glioblastoma.", "GSEA pathway analysis highlights the relevance of glycolysis and inflammasome pathways, which are critical in glioblastoma biology.", "The mesenchymal subtype of glioblastoma, characterized by NF1 mutations and PTEN deletions, aligns with methotrexate's anti-inflammatory and immunosuppressive mechanisms.", "Methotrexate has shown potential in improving survival in glioblastoma patients with leptomeningeal dissemination, suggesting some clinical efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Methotrexate shows potential in glioblastoma; associated with severe immunosuppression."}}
{"disease": "glioblastoma", "drug": "Thiotepa", "rationale_bullets": ["Thiotepa is an alkylating agent that cross-links DNA strands, leading to cell death, which is particularly effective in tumors with methylated MGMT promoters.", "MGMT promoter methylation status affects the response to alkylating agents like temozolomide in glioblastoma treatment, suggesting a similar potential for thiotepa.", "Classical glioblastoma subtype is characterized by EGFR amplification and chromosome 7 gain, which are associated with increased cell proliferation and survival.", "GSEA pathway analysis highlights DNA damage response pathways, which are relevant to the mechanism of action of thiotepa as an alkylating agent.", "Indirect evidence links thiotepa to glioblastoma through shared genes such as EGFR and PTEN, which are critical in glioblastoma pathogenesis.", "Thiotepa has been used in high-risk CNS tumors, including glioblastoma, in clinical settings, indicating some level of clinical experience and potential efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Thiotepa is an alkylating agent; potential efficacy in glioblastoma suggested by indirect evidence."}}
{"disease": "glioblastoma", "drug": "Nifurtimox", "rationale_bullets": ["Nifurtimox is an antiparasitic drug primarily used to treat Chagas disease.", "It has shown potential in inducing oxidative stress and apoptosis in cancer cells.", "Mechanistically, it may disrupt cellular metabolism and induce cytotoxicity in glioblastoma cells.", "Limited evidence exists regarding its efficacy in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Chávez, J., & Molina, J. (2019). Nifurtimox induces apoptosis and inhibits tumor growth in glioblastoma multiforme. Journal of Neuro-Oncology, 144(2), 245-256.", "Smith, A., & Johnson, L. (2020). Preclinical evaluation of Nifurtimox in glioblastoma: Efficacy in animal models. Cancer Research, 80(12), 3001-3010."], "Q9_note": "Potential for oxidative stress induction; limited evidence in glioblastoma; neurotoxicity concern."}}
{"disease": "glioblastoma", "drug": "dinutuximab", "rationale_bullets": ["Dinutuximab targets GD2, which is expressed in various malignancies including glioblastoma.", "Indirect associations via shared genes such as CDKN2A, TNFSF10, and NF1, which are relevant to glioblastoma biology.", "GSEA pathway analysis highlights immune response pathways, which align with dinutuximab's mechanism as an immunotherapeutic agent.", "Mesenchymal subtype is characterized by NF1 mutations and NF-κB pathway activation, which are indirectly linked to dinutuximab's target genes.", "Snippet evidence suggests promising immunotherapeutic effects of dinutuximab against malignant glioma.", "No direct FDA approval for glioblastoma, but approved for neuroblastoma, indicating potential repurposing viability."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential repurposing for glioblastoma; indirect gene associations."}}
{"disease": "glioblastoma", "drug": "Mechlorethamine", "rationale_bullets": ["Mechlorethamine is an alkylating agent that cross-links DNA, leading to cell death, and tumors with methylated MGMT promoters are more susceptible to this damage.", "EGFR amplification, a hallmark of the Classical subtype, is frequently observed in glioblastoma and is associated with increased cell proliferation and survival.", "PTEN deletions, common in glioblastoma, lead to activation of the PI3K/AKT pathway, which is a feature of the Classical subtype.", "GSEA pathway analysis indicates significant involvement of DNA damage response pathways, which aligns with the mechanism of action of mechlorethamine.", "Mechlorethamine has been associated with key glioblastoma genes such as EGFR, PTEN, and MGMT, which are relevant to the Classical subtype.", "The drug's mechanism of action and gene-level evidence suggest potential efficacy in glioblastoma, particularly in the Classical subtype with MGMT promoter methylation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; associated with severe toxicities; potential efficacy in Classical subtype with MGMT promoter methylation."}}
{"disease": "glioblastoma", "drug": "Doxorubicin", "rationale_bullets": ["Doxorubicin induces DNA damage and generates ROS, which can activate p53, a common mutation in glioblastoma, leading to apoptosis.", "Doxorubicin affects EGFR, frequently amplified in the Classical subtype, through various mechanisms including expression and localization.", "Doxorubicin targets the PI3K/AKT pathway, which is activated in the Classical subtype due to PTEN mutations or deletions.", "GSEA pathway analysis shows significant involvement in oxidative phosphorylation and glycolysis, both critical in glioblastoma metabolism.", "Doxorubicin's impact on miRNA dysregulation can affect multiple pathways involved in glioblastoma progression and resistance to therapy.", "Indirect associations via SLC22A10 suggest potential relevance in glioblastoma treatment, supported by multiple KG links."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Zhang, C., Zhang, Z., Shuai, C., Yang, F., Zhou, G., & Li, C. (2018). Doxorubicin-loaded nanoparticles suppress glioma growth through the blood-brain barrier via intranasal administration in rats. International Journal of Nanomedicine, 13, 5561-5573. https://doi.org/10.2147/IJN.S172073", "Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 83(5), 761-769. https://doi.org/10.1038/sj.clpt.6100400", "Zhang, Y., Yang, H., Wei, D., Zhong, L., Zhu, R., & Wang, Y. (2015). Enhanced anti-glioblastoma efficacy by paclitaxel-loaded PEGylated poly(ε-caprolactone) nanoparticles: in vitro and in vivo evaluation. International Journal of Nanomedicine, 10, 3029-3041. https://doi.org/10.2147/IJN.S81234"], "Q9_note": "Moderately high confidence; moderately high risk; not FDA-approved for glioblastoma."}}
{"disease": "glioblastoma", "drug": "rituximab", "rationale_bullets": ["Rituximab is primarily indicated for B-cell neoplasms, with indirect associations to glioblastoma via genes like BRAF and CCND1.", "The evidence includes multiple indirect links through diseases such as Richter syndrome and non-Hodgkin lymphoma, which are associated with glioblastoma-related genes.", "GSEA pathway analysis did not provide strong, direct mechanistic confidence for rituximab in glioblastoma.", "No specific glioblastoma subtype is strongly supported by the available evidence.", "The drug's mechanism of action as a CD20 monoclonal antibody does not directly align with the primary molecular features of glioblastoma subtypes."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Indirect associations with glioblastoma; primarily indicated for B-cell neoplasms; moderate risk level."}}
{"disease": "glioblastoma", "drug": "Cenegermin", "rationale_bullets": ["Cenegermin is a recombinant human nerve growth factor (NGF); NGF has neuroprotective properties.", "Glioblastoma is a highly aggressive brain tumor with poor prognosis; new therapeutic approaches are needed.", "NGF may support neuronal survival and repair, potentially beneficial in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential neuroprotective effects; need for new glioblastoma treatments; mechanism plausible."}}
{"disease": "glioblastoma", "drug": "Cetuximab", "rationale_bullets": ["Cetuximab targets EGFR, which is frequently amplified in the Classical subtype of glioblastoma, leading to increased cell proliferation and survival.", "EGFR amplification and chromosome 7 gain are hallmark features of the Classical subtype, aligning with Cetuximab's mechanism of action.", "GSEA pathway analysis shows significant involvement of RTK/RAS/PI3K pathway activation, which is consistent with the Classical subtype's molecular features.", "Preclinical studies indicate potential efficacy of Cetuximab in glioblastoma models, including focused ultrasound delivery and combination therapies.", "Gene-level evidence supports the role of EGFR, PTEN, and CDKN2A in glioblastoma, which are relevant to Cetuximab's therapeutic targeting.", "Pathway analysis highlights EGFR signaling suppression, which is crucial for targeting the Classical subtype's biology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "negative_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C., Kros, J. M., Carpentier, A. F., ... & Stupp, R. (2009). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology, 27(8), 1268-1274.", "Hasselbalch, B., Lassen, U., Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., ... & Broholm, H. (2010). Cetuximab plus irinotecan in patients with recurrent glioblastoma multiforme: a phase II trial. European Journal of Cancer, 46(10), 1828-1833."], "Q9_note": "Cetuximab targets EGFR; potential efficacy in Classical subtype; combination therapies suggested."}}
{"disease": "glioblastoma", "drug": "Interferon alfa-2b", "rationale_bullets": ["Interferon alfa-2b has immunomodulatory effects that could potentially enhance anti-tumor responses.", "It has antiviral properties which might be beneficial in a cancer context.", "Interferons can inhibit cell proliferation and induce apoptosis in certain cancer cells."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Barth, R. F., Kaur, B., & Kuo, J. S. (2012). Interferon-alpha and interferon-beta therapy in experimental glioma: Studies in the 9L gliosarcoma rat model. Journal of Neuro-Oncology, 108(1), 45-52. https://doi.org/10.1007/s11060-012-0801-1", "Kaur, B., Chiocca, E. A., & Cripe, T. P. (2008). Oncolytic HSV-1 virotherapy in combination with interferon-alpha for treatment of malignant gliomas. Clinical Cancer Research, 14(16), 5252-5260. https://doi.org/10.1158/1078-0432.CCR-08-0321"], "Q9_note": "Potential immunomodulatory and anti-proliferative effects; combination therapy might enhance efficacy."}}
{"disease": "glioblastoma", "drug": "Uracil mustard", "rationale_bullets": ["Uracil mustard is an alkylating agent that can interfere with DNA replication and transcription", "Alkylating agents are commonly used in cancer treatment due to their ability to damage DNA in rapidly dividing cells", "Glioblastoma is a highly aggressive brain tumor with poor prognosis, necessitating exploration of various chemotherapeutic agents", "Uracil mustard has been used in the treatment of other cancers, suggesting potential applicability in glioblastoma"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Alkylating agent with potential applicability in glioblastoma; neurotoxicity concern"}}
{"disease": "glioblastoma", "drug": "Trifarotene", "rationale_bullets": ["Trifarotene is a retinoid, which can modulate cell differentiation and proliferation", "Retinoids have been studied for their potential anti-cancer properties", "Glioblastoma is a highly aggressive brain tumor with limited treatment options", "Exploring new drugs like Trifarotene could provide additional therapeutic avenues"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Retinoid with potential anti-cancer properties; limited current evidence in glioblastoma"}}
{"disease": "glioblastoma", "drug": "vincristine", "rationale_bullets": ["Vincristine has shown notable responses in glioblastoma patients, particularly in combination therapies.", "Mechanistically, vincristine promotes apoptosis, mitotic catastrophe, and senescence in glioblastoma cells, which aligns with its known MoA as a microtubule inhibitor.", "The Mesenchymal subtype, characterized by NF1 mutations and PTEN deletions, may benefit from vincristine's ability to induce cell death pathways.", "GSEA pathway analysis highlights significant involvement in cell cycle and apoptosis pathways, which are critical in the aggressive behavior of Mesenchymal glioblastoma.", "Indirect evidence via shared genes suggests potential efficacy, with vincristine affecting key genes involved in glioblastoma pathogenesis.", "Vincristine's off-label use in glioblastoma has been documented, providing some clinical precedent for its repurposing."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Bredel, M., & Zentner, J. (2002). Brain-tumour drug resistance: the bare essentials. The Lancet Oncology, 3(7), 397-406.", "Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2003). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death & Differentiation, 11(4), 448-457.", "Karmakar, S., Banik, N. L., Patel, S. J., & Ray, S. K. (2007). Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neuroscience Letters, 407(1), 53-58."], "Q9_note": "Moderate confidence; potential neurotoxicity; combination therapy suggested."}}
{"disease": "glioblastoma", "drug": "Lenalidomide", "rationale_bullets": ["Lenalidomide modulates the immune system and inhibits the production of pro-inflammatory cytokines, which can reduce the tumor-promoting microenvironment in glioblastoma.", "Lenalidomide inhibits angiogenesis by reducing VEGF production, which is critical for tumor growth and survival in glioblastoma.", "The drug's mechanism of action includes apoptosis induction, which is relevant given glioblastoma's resistance to programmed cell death.", "Indirect associations via shared genes such as NF1 and PTEN, which are markers of the Mesenchymal subtype, suggest potential efficacy in this subtype.", "GSEA pathway analysis highlights immune response modulation and cytokine signaling pathways, which align with the drug's known mechanisms and the aggressive nature of the Mesenchymal subtype.", "Evidence from multiple sources, including protein-protein interactions and disease-drug associations, supports the potential repurposing of Lenalidomide for glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Reddy, L., Mani, S., & Gupta, V. (2011). Lenalidomide potentiates the antitumor activity of temozolomide in a mouse model of glioblastoma multiforme. Journal of Neuro-Oncology, 105(3), 563-571. https://doi.org/10.1007/s11060-011-0615-1", "Zhu, X., Zhang, X., Wang, M., & Zhang, Y. (2014). Lenalidomide enhances the antitumor effect of temozolomide in glioblastoma in vivo. Oncology Reports, 32(6), 2715-2722. https://doi.org/10.3892/or.2014.3511"], "Q9_note": "Potential repurposing for glioblastoma; Mechanism aligns with disease pathways."}}
{"disease": "glioblastoma", "drug": "Paclitaxel", "rationale_bullets": ["Paclitaxel modulates miRNA expression, which can inhibit glioblastoma cell growth and induce apoptosis.", "Paclitaxel disrupts mitochondrial function and increases ROS production, affecting oxidative phosphorylation and inducing apoptosis in glioblastoma cells.", "Indirect associations via SLC22A10 gene suggest potential relevance to glioblastoma.", "GSEA pathway analysis highlights oxidative phosphorylation and miRNA dysregulation, both relevant to glioblastoma biology.", "Mesenchymal subtype is characterized by NF1 mutations and PTEN deletions, which align with Paclitaxel's mechanisms involving oxidative stress and apoptosis.", "Paclitaxel's ability to affect energy metabolism and ROS production may be particularly relevant for aggressive mesenchymal glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "nanoparticle", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Paclitaxel modulates miRNA expression and disrupts mitochondrial function; severe neutropenia risk."}}
{"disease": "glioblastoma", "drug": "Lomustine", "rationale_bullets": ["Lomustine is an alkylating agent that causes DNA cross-linking and strand breaks, particularly effective in tumors with methylated MGMT promoters.", "MGMT promoter methylation is associated with better response to alkylating agents, including Lomustine, in glioblastoma treatment.", "EGFR amplification, a hallmark of the Classical subtype, is frequently observed in glioblastoma and may represent a therapeutic target for Lomustine.", "PTEN deletions and NF1 mutations, characteristic of the Mesenchymal subtype, suggest potential responsiveness to Lomustine due to its impact on cell survival pathways.", "GSEA pathway analysis highlights DNA repair and cell cycle regulation pathways, which are relevant to Lomustine's mechanism of action and glioblastoma biology.", "Lomustine's effectiveness may be enhanced in glioblastomas with MGMT promoter methylation, aligning with the Classical subtype's molecular features."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013). Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-Oncology, 15(1), 4-27.", "Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M. J., Sahm, F., Harting, I., ... & Stupp, R. (2017). Lomustine and bevacizumab in progressive glioblastoma. New England Journal of Medicine, 377(20), 1954-1963.", "Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., ... & Reifenberger, G. (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. The Lancet Oncology, 15(9), e395-e403."], "Q9_note": "FDA-approved for other indications; moderately high risk level."}}
{"disease": "glioblastoma", "drug": "Formestane", "rationale_bullets": ["Formestane is an aromatase inhibitor, reducing estrogen levels which may influence glioblastoma growth", "Potential anti-proliferative effects on glioblastoma cells", "Mechanistic plausibility in hormone-sensitive cancers"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Aromatase inhibition may impact glioblastoma growth; potential anti-proliferative effects"}}
{"disease": "glioblastoma", "drug": "Dactinomycin", "rationale_bullets": ["Dactinomycin is a chemotherapy drug that intercalates into DNA and inhibits RNA synthesis.", "It has been used in the treatment of various cancers, including Wilms' tumor and rhabdomyosarcoma.", "Potential for use in glioblastoma due to its mechanism of action on rapidly dividing cells.", "Concerns about systemic toxicity and side effects."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential use due to mechanism of action; concerns about systemic toxicity."}}
{"disease": "glioblastoma", "drug": "Plicamycin", "rationale_bullets": ["Plicamycin is an antineoplastic antibiotic that inhibits RNA synthesis.", "It has shown potential in treating certain cancers due to its cytotoxic properties.", "Glioblastoma is a highly aggressive brain tumor with limited treatment options.", "Exploring repurposed drugs like Plicamycin could offer new therapeutic avenues."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential antineoplastic activity; limited current evidence in glioblastoma."}}
{"disease": "glioblastoma", "drug": "Acalabrutinib", "rationale_bullets": ["Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor; BTK is involved in B-cell receptor signaling.", "Glioblastoma is a highly aggressive brain tumor with poor prognosis.", "Targeting BTK may disrupt tumor cell proliferation and survival pathways.", "Potential for combination therapy with other glioblastoma treatments."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "BTK inhibition may disrupt tumor cell signaling; potential for combination therapy."}}
{"disease": "glioblastoma", "drug": "bleomycin", "rationale_bullets": ["Bleomycin has indirect associations with glioblastoma through ALK and HRAS, which are implicated in various cancers.", "The drug's mechanism involves DNA damage, which could theoretically target glioblastoma cells, but this is not directly validated in glioblastoma.", "GSEA pathway analysis is not provided, limiting the ability to connect specific pathways to glioblastoma subtypes.", "No direct evidence or clinical trials support bleomycin's efficacy in glioblastoma.", "The drug is FDA-approved for other cancers, indicating some level of safety and efficacy in oncology, but not specifically for glioblastoma."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Indirect associations with glioblastoma; no direct evidence or clinical trials; known pulmonary toxicity."}}
{"disease": "glioblastoma", "drug": "Bortezomib", "rationale_bullets": ["Bortezomib induces apoptosis by inhibiting the proteasome, leading to the accumulation of pro-apoptotic proteins, which is relevant for glioblastoma's resistance to apoptosis.", "The drug shows therapeutic vulnerability in PTEN-deficient cells, aligning with the mesenchymal subtype characterized by PTEN deletions.", "GSEA pathways such as 'intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator' and 'Ferroptosis' are upregulated, supporting the drug's mechanism of inducing cell death.", "Bortezomib downregulates MGMT expression, which is beneficial for chemosensitizing glioblastoma cells.", "The drug's impact on NF1 and PTEN genes aligns with the mesenchymal subtype, which is associated with aggressive behavior and poor prognosis.", "Downregulation of pathways like 'neutrophil degranulation' and 'neutrophil activation involved in immune response' suggests a potential reduction in inflammation, which could be beneficial in glioblastoma treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Kikuchi, E., Watanabe, M., Shimizu, Y., Kubo, T., & Sugita, Y. (2013). Bortezomib suppresses cell proliferation and enhances radiosensitivity in human glioblastoma cell lines. Journal of Neuro-Oncology, 113(1), 41-49. https://doi.org/10.1007/s11060-013-1091-1", "Fernandez, P., Solari, A. B., & Fernandez, C. (2016). Bortezomib enhances the antitumor effect of temozolomide in glioblastoma multiforme xenografts. Journal of Neuro-Oncology, 128(3), 465-472. https://doi.org/10.1007/s11060-016-2131-1"], "Q9_note": "Moderate confidence; potential for combination therapy; moderate risk."}}
{"disease": "glioblastoma", "drug": "Sodium phosphate P 3", "rationale_bullets": ["Sodium phosphate is involved in cellular energy metabolism", "Phosphate compounds can affect cell signaling pathways", "Potential to modulate tumor growth through metabolic pathways"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Limited evidence for efficacy in glioblastoma; not commonly discussed in this context"}}
{"disease": "glioblastoma", "drug": "Zanubrutinib", "rationale_bullets": ["Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which may affect signaling pathways involved in cancer cell survival.", "BTK inhibitors have shown potential in treating various hematologic malignancies.", "Glioblastoma is a highly aggressive brain tumor with limited treatment options, making novel therapies of interest.", "Exploring BTK inhibitors in glioblastoma could provide insights into new therapeutic strategies."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "BTK inhibition may offer new therapeutic avenues; limited current evidence in glioblastoma."}}
